The safety and antiviral efficacy of stavudine extended release formulation as compared to stavudine immediate release formulation, each as part of potent antiretroviral combination therapy

Trial Profile

The safety and antiviral efficacy of stavudine extended release formulation as compared to stavudine immediate release formulation, each as part of potent antiretroviral combination therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Efavirenz (Primary) ; Lamivudine (Primary) ; Stavudine (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 19 Dec 2006 Status change
    • 12 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top